Abstract
Metabolic disorders (MDs) are a group of medical conditions that impact the metabolism. These complex processes may have common characteristics among various diseases, thereby suggesting the potential of drug repurposing. Employing Mendelian Randomization (MR), we constructed a causal network between 2,478 targetable drug-gene expressions (eQTLs) and 30 broadly reported metabolic disorders. Our study identified 499 drug target genes significantly associated with 27 metabolic disorders (|MR coefficient| > 0.2). Pathway enrichment analysis of drug target genes indicates that regulation of response stimulus may serve as a common pathway across 14 diseases. Based on 53 commonly used clinical drugs for 18 diseases, we elucidated novel therapeutic mechanisms of some drugs, such as the potential of Valproic Acid to treat Schizophrenia by affecting key genes in Alcoholism, SLC29A1, and HDAC4. Furthermore, we identified potential for drug repurposing in four diseases, with Manic Episode and Type 1 Diabetes sharing four novel drugs: Cannabidiol, Doxorubicin, Genistein, and Propylthiouracil. Additionally, we predicted 189 potential therapeutic drugs affecting the causal genes of diseases. Overall, we established a causal network between metabolic disorders and drug target genes, explored possible pathways for drug action on disease treatment, and proposed drug repurposing strategies for four diseases.
Highlights
To the best of our understanding, the manuscript we have submitted delineates the inaugural drug-gene causal network tailored for Metabolic Disorders (MDs), covering an array of 30 diseases.
This investigation unveils potential novel drug mechanisms aimed at treating MDs, marking a pioneering exploration in this domain.
We introduce strategies for the repurposing of drugs targeting four specific MDs, suggesting innovative approaches to treatment.
The findings are presented through an easily navigable web interface, enabling thorough examination by users (https://quantlifebits.shinyapps.io/mrmetabopharm/).
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study received financial support from National Natural Science Foundation of China grants (#82300574); National Natural Science Foundation of China (#62205065); China Postdoctoral Science Foundation Funded Project (#2022M720771). China Postdoctoral Science Foundation (#2023M730628).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
https://www.finngen.fi/en
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data generated are available online
